Could a stronger blood thinner cut repeat stroke risk?

NCT ID NCT07746882

Not yet recruiting Prevention Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether anticoagulant medications (like rivaroxaban or apixaban) are better than aspirin at preventing a second stroke in people who have had an ischemic stroke of unclear cause. Participants are adults who had a stroke within the past two weeks and show signs that might benefit from stronger blood thinning. The study compares the two approaches over three months to see which is safer and more effective at reducing recurrent strokes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anticoagulation therapy (rivaroxaban, edoxaban, apixaban, or dabigatran) compared with antiplatelet therapy (aspirin or alternatives)
What this could lead to: If anticoagulants prove more effective, they could become a standard preventive treatment for certain stroke survivors, reducing the risk of another stroke.
What could go wrong: This is a phase 3 trial, but results may not apply to all stroke patients. Anticoagulants carry a risk of bleeding, which could offset benefits in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE STROKE

More trials for these conditions

Other studies related to the condition(s) this trial covers.